ข่าวประชาสัมพันธ์ Acute Myeloid Leukemia+the Menarini Group

Menarini Ricerche to Sponsor Cancer Trial in Acute Myeloid Leukemia in USA

Menarini Ricerche, a company of the Menarini Group, announced today that the sponsorship of the ongoing Phase I/II study that is investigating MEN1703/SEL24 for the treatment of patients with relapsed/refractory (R/R) AML in the USA has been transferred from Selvita to Menarini Ricerche on June 30th 2018. (Logo: http://mma.prnewswire.com/media/520214/Menarini_Ricerche_Logo.jpg ) Selvita S.A. and Menarini Group entered into a global licensing agreement for SEL24/MEN1703 on March 28th, 2017

06 สิงหาคม 2561 11:32 น.

The Menarini Group Announces ELZONRIS(R) (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare

Japanese Ministry of Health, Labor and Welfare grants Orphan Drug Designation to tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN) The... ก.ย. 66

BOTTICELLI, THE INQUIETUDE AND THE BEAUTY - Menarini presents in Florence its latest art monograph, dedicated to the symbol of the Italian Renaissance

Successful artist, sensitive interpreter of the culture of his time and author of extraordinarily relevant works, Sandro Botticelli was a master of... พ.ค. 66

Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting

The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group,... พ.ค. 66

Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO(R) (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Mult

- Based on Results from Phase 3 BOSTON Study, ... ก.พ. 66

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer Carrick Therapeutics, an oncology-focused... ธ.ค. 65

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group (... พ.ย. 65

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

- Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myelom... ก.ค. 65

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

- Combines NewAmsterdam's lead clinical program obicetrapib with Menarini's deep cardiovascular disease and regional expertise - Total deal value of over EUR1 billion; including EUR142.5 million... มิ.ย. 65

Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

European Commission Decision Anticipated within Approximately 60 Days Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical... พ.ค. 65

Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO(R) (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

TIBSOVO is the first targeted therapy to show improved event-free survival and overall surv... ส.ค. 64

Menarini Asia-Pacific strengthens Men's Health portfolio in China with acquisition of Cialis(R) (Tadalafil) from Lilly

Acquisition of Cialis(R) in the People's Republic of China to bolster Menarini's Men's Health portfolio and drive multichannel coverage This is a significant milestone for Menarini... ก.ค. 64

Radius Health & Menarini Group Provide Elacestrant Update

- Target enrollment milestone reached in the Phase 3 EMERALD study - Life cycle planning advancing in parallel with current Phase 3 monotherapy program Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menarini Group today... ก.ย. 63

Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia

Invivoscribe, Inc., an industry pioneer and global leader in the field of precision diagnostics announces the launch of a fully integrated drug development engine.... ก.ค. 63

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

Licensing rights are worldwide excluding US, Canada, Japan and South AmericaHelsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Menarini, an Italian biopharmaceutical Group active in... ธ.ค. 61

Menarini Ricerche พบผลเชิงบวกเกี่ยวกับกลไกการออกฤทธิ์ของยาทดลอง MEN1112/OBT357 ต่อเซลล์ไลน์มะเร็งเม็ดเลือดขาวเฉียบพลันชนิดไมอิลอยด์ พร้อมเตรียมนำเสนอผลงานวิจัยที่การประชุม 60th Annual SIC Meeting

ในวันที่ 20 กันยายนนี้ Menarini Ricerche จะนำเสนอข้อมูลการวิจัยพรีคลินิกที่งานประชุมประจำปีครั้งที่ 60... ก.ย. 61

Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting

Menarini Ricerche will present tomorrow, September 20th, at the 60th Annual Meeting of the Italian Cancer Society (SIC), new preclinical data showing that pre... ก.ย. 61

AsiaNet Daily Summary Press Releases For Thursday May 30, 2002

CLINICAL TRIAL... CAMBRIDGE: Patients suffering from Acute Myeloid Leukemia have been selected by biopharmaceutical company, Millenium Pharmaceuticals, to take part in a clinical trial of a new cancer fighting drug to assess its safety... พ.ค. 45